Early sensitivities of creatine kinase (OK), CKMB (activity and mass), CKMM and CKMB isoform ratios, myoglobin, cardiac troponin I (cTnl), and cardiac troponin T (cml) were compared to find the most sensitive serum marker for acute myocardial infarction (AMI)during the first hours after onset of chest pain. In a prospective study we investigated 37 consecutive patients with AMI who were admitted to the coronary care unit within 4 h after onset of chest pain. Blood samples were drawn every hour for the first 10 h after admission. CKMB mass concentrations, CKMM and CKMB isoform ratios, myoglobin, cTnI, and cTnT increased significantly (P 0.0067) earlier than OK and CKMB activity and were also significantly (P sO.046) and markedly more sensitive on admission. Differences in early sensitivities of myoglobin, CKMB mass, CK isoform ratios, cTnl, and cTnT were small and not significant. Therefore,turnaround time and practicality for emergency determination of methods, specificities of markers, the required specificity in the individual patient, and costs mainly determine the choice among myoglobin, CKMB mass, CK isoforms, cTnI, and cTnT. ECGs at the time of presentation to the emergency department (1,2). The conventional serum markers creatine kinase (CK) and CKMB activity are usefl.il for retrospective confirmation of myocardial infarction in these patients, but neither is very helpful in the emergency department evaluation of the patient with chest discomfort (4). The search for more sensitive biochemical markers for the early diagnosis of AM! (4, 5) reflects the need for an improved initial diagnostic accuracy of biochemical markers in patients with acute chest pain. Several biochemical markers (myoglobin, CKMB mass concentration, CK isoform ratios) have been proposed for the early diagnosis of AMI during recent years. All of them are markedly more sensitive than CK and CKMB activity during the early hours after the onset of infarct-related symptoms (6-8). Myoglobin and CKMM isoform ratio measurements are less heart-specific than CKMB isoenzyme and isoform ratio determination (5). However, CKMB is not an absolutely heartspecific marker either (5, 9). Therefore, because of their extraordinary high specificity for myocardial damage, cardiac troponins I and T (cTnI, cThT) have gained particular interest (5,9). Both exist in three different isoforms with an unique structure in striated muscles, one for slow-twitch, one for fast-twitch, and one for cardiac muscle (10, 11). The troponin complex consists of three subunits and is involved in the calciumsensitive switch that regulates the interaction of actin and myosin in striated muscles. cThT (Mr 37 000) binds the troponin complex to tropomyosin, and cThI (Mr 22 500) is the inhibitory subunit of the troponin complex (5, 9). The clinical specfficity of cThT is limited by recent reports on discordances between serum cThT and cTnI in renal disease (12, 13) and by the possibility of a reexpression of cTnT in chronically stressed skeletal muscle (14)-which has not, however, been demonstrated in humans so far. Increased cTnI concentrations have been found only after myocardial damage up to now (5,9, 11).
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ing AMI within 1 h (3). Although electrocardiography (ECG) is considered the simplest, most convenient, most reliable, and most reproducible method for early diagnosis of AM!, approximately half of all AM! patients have nondiagnostic ECGs at the time of presentation to the emergency department (1,2). The conventional serum markers creatine kinase (CK) and CKMB activity are usefl.il for retrospective confirmation of myocardial infarction in these patients, but neither is very helpful in the emergency department evaluation of the patient with chest discomfort (4) . The search for more sensitive biochemical markers for the early diagnosis of AM! (4, 5) reflects the need for an improved initial diagnostic accuracy of biochemical markers in patients with acute chest pain. Several biochemical markers (myoglobin, CKMB mass concentration, CK isoform ratios) have been proposed for the early diagnosis of AMI during recent years. All of them are markedly more sensitive than CK and CKMB activity during the early hours after the onset of infarct-related symptoms (6-8). Myoglobin and CKMM isoform ratio measurements are less heart-specific than CKMB isoenzyme and isoform ratio determination (5). However, CKMB is not an absolutely heartspecific marker either (5, 9). Therefore, because of their extraordinary high specificity for myocardial damage, cardiac troponins I and T (cTnI, cThT) have gained particular interest (5,9). Both exist in three different isoforms with an unique structure in striated muscles, one for slow-twitch, one for fast-twitch, and one for cardiac muscle (10, 11). The troponin complex consists of three subunits and is involved in the calciumsensitive switch that regulates the interaction of actin and myosin in striated muscles. cThT (Mr 37 000) binds the troponin complex to tropomyosin, and cThI (Mr 22 500) is the inhibitory subunit of the troponin complex (5, 9). The clinical specfficity of cThT is limited by recent reports on discordances between serum cThT and cTnI in renal disease (12, 13) and by the possibility of a reexpression of cTnT in chronically stressed skeletal muscle (14) -which has not, however, been demonstrated in humans so far. Increased cTnI concentrations have been found only after myocardial damage up to now (5,9, 11).
Rapid and specific assays for measurement of myo- Marburg, Germany). The detection limit of this assay is 50 g/L. The URL is 70 g/L (7).
cThT. cThT was measured by an enzyme immunoassay (Boehringer Mannheim, Mannheim, Germany) specific for cThT (22) . The URL is 0.1 g/L (21,23).
cThI. We measured cTnI by a highly specific enzyme immunoassay (Sanofi Diagnostics Pasteur, Marnes-la-
The URL is 0.1 p.g/L (24), which was confirmed previously (25). Creatine kinase isoforms.
CKMM
and CKMB isoform ratios were determined by high-voltage electrophoresis (REP, Helena Labs.). The isoforms were sep.
#{149}
In 37 AMP patients before thrombotytic therapy. Total CKMB activities were below the detection limit of the immunoinhibition method in all 27 subjects. The MB isoenzyme with its isoforms could not be detected by high-voltage electrophoresis either. We used 1.5 as the cutoff for the CKMB2/CKMB, isoform ratio, which is recommended by the developers of the method and the manufacturer, and which was repeatedly confirmed previously (8, 19,26-28) .
The precision of the CKMB isoform separation was tested by using a plasma pool with a CI MB/CKMB1 ratio of 1.4. The intraassay and interassay CVs were 6.5% (n = 10) and 9.5% (n = 13), respectively.
The precision of the CKMM isoform separation was tested with a commercially available CK contol serum (CK isotrol; Sigma Diagnostics, St. Louis, MO) with a CKMM3/CKMM1 ratio of 1.1. The intraassay and interassay CVs were 7.5% (n = 10) and 10.9% (n = 10), respectively.
EarlySensitivitiesand Time Coursesof Markersafter Myocardial Infarction
On admission before the start of thrombolytic treatment (0-4-h period after the onset of chest pain), CK and CKMB activities were significantly (P 0.046) less frequently increased than the other markers, and there were no significant differences in the frequencies of increased values of myoglobin, CKMB mass, CK isoform ratios, cTnI, and cTnT. The sensitivities of the latter two were roughly identical (Table 1) (Tables 3 and 4) . However, there were no significant differences in times to first increases above URL between myoglobin, CKMB mass, CK isoform ratios, cTnI, and cTnT (Friedman test, P = 0.21). The early sensitivities of markers according to time from the onset of chest pain in these 37 patients are listed in Table 3 . Myoglobin, CK isoform ratios, CKMB mass, cTnJ, and cThT were significantly (P <0.025) and markedly more sensitive than CKMB activity during the 2-6-h period after the onset of chest pain. All were significantly (P <0.05) and markedly more sensitive than CK activity during the 3-4-h period (see Table 3 ). Up to 3 h from the onset of chest pain the sensitivities of myoglobin, CK isoform ratios, CKMB mass, cTnl, and cThT were almost identical; during the 3-6-h period CKMB mass and myoglobin tended to be more sensitive than the others. CKMB mass was the tendentiously most sensitive marker of all tested. The sensitivities of myoglobin, CK isoform ratios, cTnI, and cTnT were mostly within the 95% confidence interval of CKMB mass (see Table 3 ). We found small, significant (P <0.05) differences between CKMB mass and CKMM isoform ratios at 4, 5, and 6 h, and between CKMB mass and CKMB isoform ratios as well as the troponins at 4 and 5 h after the onset of chest pain.
Comparing the sensitivities of all markers during the 0-4-h period after the onset of chest pain before thrombolytic therapy with the sensitivities of markers during the same period when samples drawn after thrombolytic therapy were not excluded revealed that the sensitivities of all tested markers were significantly (P 0.04) and markedly higher after thrombolytic therapy (Tables 1 and 3 ). However, in both groups the sensitivities of CK and CKMB activities were and markedly lower than those of the other investigated markers; no significant differences were seen among CKMB isoform ratios, CKMB mass, myoglobin, and the troponins. Subgroup analysis in patients with Q-wave AMI (divided into patients with and without early reperfiision) and non-Q-wave AMI revealed similar results (Table 4) . In early reperfused Q-wave AMI and non-Qwave AMI patients, first increased values of all markers were observed earlier than in Q-wave AMI patients without early reperfusion of the infarct-related coronary artery.
The differences did not yield statistical significance because of the relatively small group of AMI patients without early reperfusion (n = 6). Times to first increases in non-Q-wave AMI and Q-wave AMI with early reperfi.ision were almost identical. Within each subgroup CK and CKMB activity increased later than the other markers. The differences between myoglobin, CKMB mass, CK isoform ratios, cTnJ, and cThT were small (Table 4) .
Every tested marker was increased above URL in all investigated AMI patients. Marker concentration time courses of early reperfused Q-wave AMI patients (largest subgroup, n = 19) during the first 24 h after the onset of chest pain are shown in Fig. 1 . In every patient of this subgroup all markers showed a pattern with a rise and fall except for four patients with only a falling pattern of CKMB isoform ratio. Myoglobin, CKMB mass, CK isoform ratios, cTnI, and cThT increased parallel to each other (see Fig. 1 and Table 4) . Peak values of markers were found at 9.25 (median; interquartile range 8-12) h after onset of chest pain for CKMB activity, 9.5 (7.4-10.1) h for CK activity, 6 (5-7.75) h for CKMM isoform ratio, 4(3-7) h for CKMB isoform ratio, 12 (9.25-12) h for cTnT, 8 (6.1-10) h for cTnI, 4 (3.5-6) h for myoglobin, and 8.5 (7-10) h for CKMB mass (Fig. 1) . Almost all individual marker time courses of these 19 patients had only one peak during the first 24 h after the onset of chest pain (time period shown in Fig. 1) . Two peak values were found in two patients for the CK isoform ratios and in one patient for CK, CKMB activity, and CKMB mass. In contrast to the other markers, myoglobin (median time to peak 24, interquartile range 16.5-36 h) and the CK isoform ratios (MB ratio: median 16.9, interquartile range 12-24 h; MM ratio: median 20, interquartile range 16.1-24 h) frequently returned to normal within 24 h after the onset of infarction (see Fig. 1 ).
Discussion
In contrast to previous studies on early sensitivities of biochemical markers for AMI, we tested in this study the same cohort of AMI patients for myoglobin, CK isoforms, CKMB mass and activity, CK activity, cTnI, and cTnT. These markers are already or will be soon This is highlightened by the fact that we obtained equal results in blood samples withdrawn before and after thrombolytic treatment. In both circumstances CK and CKMB activity were markedly less sensitive than myoglobin, CKMB mass, CK isoform ratios, cTnI, and cTnT, and there were no significant differences among the latter five. The comparison of sensitivities within 4 h after the onset of chest pain in samples drawn before thrombolytic treatment and samples collected after the start of thrombolysis revealed that the sensitivities of all markers were markedly higher in the latter group, which is in accordance with previous reports (17, 29,30) .
The chronological order of increases in markers was the same regardless of whether reperfusion had occurred or not. However, first increases in all markers were observed later in patients without early recanalization.
Therefore, the very high sensitivities of markers >4 h after the onset of chest pain, shown in and the sensitivities of markers that we report in this study are in the range of previously published values. We confirm that myoglobin, CKMB mass, and CK isoform ratios are more sensitive during the first hours after onset of AMI than are CK and CKMB activity (4, 6-8, 19,27,28) . Similar to earlier reports, the early sensitivities of myoglobin, CKMB mass, and cThT were in the same range (9,21,31 There are currently no biochemical guidelines for commencing thrombolytic therapy, and our reported sensitivities of markers before thrombolytic therapy during the 0-4-h period after the onset of chest pain are too low to make it very likely that myoglobin, CKMB mass, CK isoform ratios, cTnI, or cTnT will play a major role for the decision to administer thrombolytic therapy in the future as well. Serum markers are, however, important to confirm a suspected myocardial infarction, may decide the diagnosis in difficult cases, and may be useful for more rapid and accurate triaging of chest-pain patients, a procedure for which demand is increasing (35). We found that early sensitivities of myoglobin, CKMB mass, CK isoform ratios, cThI, and cTnT are roughly equivalent.
The differences were small and are not deemed to be clinically relevant. Therefore, the debate on the choice of markers will focus on their specificities.
In this respect, the clinical specificities of myoglobin and CKMB on admission to the emergency department are comparable in nontraumatic chestpain patients (7,36), which we also expect for CKMM isoform ratio and CKMB in this preselected population. On the other hand, in a patient with concomitant skeletal muscle damage, even CKMB determination may not be very helpful, and cTnl or cThT are required (5,9); in patients with renal diseases and suspected myocardial injury, only cTnI measurement will allow definitive diagnosis (12, 13). In addition, differences in cross-reactivities of troponin assays with their skeletal muscle isoforms, which affect clinical specificity of test results, have to be considered in patients with concomitant skeletal muscle injury.
In summary,
we could demonstrate by frequent blood sampling that it is often possible to diagnose an AMI on the basis of positive test results of new biochemical markers even at a time when CK and CKMB activities are stifi within the reference interval. Therefore, myoglobin, CKMB mass, CK isoform ratios, cThI, or cThT should replace CK and CKMB activity measurements for ruling in AM! during the early period after its onset. The differences in early sensitivities of new markers were small and are hardly of clinical relevance. Consequently, apart from early sensitivity, the choice among myoglobin, CKMB mass, CK isoforms, cTnI, and cThT should be mainly based on turnaround time and practicality for emergency determination of methods, specificity of markers, required clinical specificity in the individual patient, laboratory equipment, and finally costs of determination.
The reagents for marker determination were gifts from the assays' manufacturers.
The REP electrophoresis unit was a loan from Heintel (Vienna, Austria).
